Skip to main content

Table1 The characteristics of various phenotypes of PCOS using Rotterdam criteria

From: The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study

Phenotype characteristic

Group 1 (n = 66) ANOVU+ HA ± PCO

Group2 (n = 43) HA + PCO

Group3 (n = 27) ANOVU + PCO

Normal (n = 423)

Age (years)

31.0 (25.8-37.3)*

30.0 (25.0-40.0)*

35.0 (28.0-39.0)

36.0 (30.0-41.0)

BMI (kg/m2)

27.0 (25.8-37.3)

25.0 (21.6-29.2)

25.6 (23.0-31.2)

26.4 (23.1-29.4)

WHR

0.81 (0.76-0.85)

0.78 (0.75-0.85)

0.83 (0.78-0.86)

0.81 (0.76-0.85)

Systolic Blood Pressure (mm/Hg)

110.0 (100.0-120.0)

100.0 (105.0-110.0)

110.0 (100.0-110.0)

110.0 (100.0-120.0)

Diastolic Blood Pressure (mm/Hg)

70.0 (60.0-80.0)

70.0 (60.0-70.0)

70.0 (60.0-70.0)

70.0 (60.0-80.0)

% Women with history of Primarily infertility

27.3*

21.6*

31.0*

10.6

% women with family history of HA

42.4*

20.9

11.1

14.0

% women with family history of ANOVU

36.4*†‡

14.0

22.2

19.0

LH/FSH Ratio

0.77 (0.46-1.04)

0.64 (0.45-1.0)

0.69 (0.5-1.1)

0.6 (0.43-0.86)

Total T (ng/ml)

0.75 (0.57-0.88) *‡

0.81 (0.52-0.93) *††

0.41 (0.29-0.53)

0.51 (0.32-0.68)

FAI

4.7 (3.1-6.9) *‡

4.9 (3.6-7.1) *††

2.2 (1.3-2.8)

2.6 (1.5-3.7)

A4 (ng/ml)

5.8 (5.1-6.9) *‡

2.1 (1.8-2.5) *††

1.1 (0.9-2.0)

1.1 (0.9-1.7)

DHEAS (μg/Dl)

196.1 (149.5-238.1) *‡

200.5 (138.9-248.0) *††

141.5 (45.7-186.7)

138.0 (58.3-192.8)

SHBG (nmol/L)

54.8 (42.7-70.7) *

54.4 (45.0- 67.1) *

62.6 (49.1-88.1)

67.2 (53.4-92.4)

  1. Values are given as median (Inter quartile range), +The hormonal and biochemical assessments of those women who use insulin sensitizers and/or oral contraceptive pills were not included for statistical analysis. * = versus normal group, p < 0.008, † = Group1 versus Group2, P < 0.008; ‡ = Group 1 versus Group 3; † † = Group2 versus Group3, p < 0.008; WHR, waist to hip ratio; Normal group, eumenorrheic and without HA and PCO; ANOVU, oligo/anovulation; HA, hyperandrogenemia and/or hyperandrogenism; PCO,polycystic ovaries; DHEAS, Dehydroepiandrosterone sulfate; Total T, Total testosterone; A4, Androstendion; SHBG, Sex Hormone Binding Globulin; FAI, Free androgen index.